AlphaCentric Advisors’s Perspective Therapeutics CATX Stock Holding History

AlphaCentric Advisors’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-80,000	Closed	-$1.07M	–	220
2024 Q3	$1.07M	Sell	80,000 -2,000	-2%	-$26.6K	0.79%	43
2024 Q2	$818K	Sell	82,000 -93,676	-53%	-$1.35M	0.6%	58
2024 Q1	$2.09M	Buy	+175,676	New	+$1.5M	1.26%	22

Other funds holding CATX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

NWMG

Nicholson Wealth Management Group Charlestown, South Carolina $172M AUM 10.38% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AlphaCentric Advisors's CATX Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Perspective Therapeutics (CATX) in Q4 2024, closing a stake of 80,000 shares — an estimated $1.07M sold.

AlphaCentric Advisors first reported a position in CATX in Q1 2024 and held it in 3 quarters. The position peaked at $2.09M in Q1 2024. 135 funds tracked by Wall St. Rank hold CATX as of Q4 2024.

AlphaCentric Advisors reported no remaining Perspective Therapeutics position as of Q4 2024 after selling out during the quarter.
AlphaCentric Advisors sold 80,000 Perspective Therapeutics shares in Q4 2024, an estimated $1.07M.
AlphaCentric Advisors first reported a position in Perspective Therapeutics in Q1 2024 and held it in 3 quarters.
AlphaCentric Advisors's Perspective Therapeutics position peaked at $2.09M in Q1 2024.
135 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.